natgillin/translations-raw huggingface dataset:
There is a linear correlation between edoxaban plasma concentration and anti-FXa activity regardless of renal function. 
Med koncentracijo edoksabana v plazmi in aktivnostjo proti faktorju Xa je bila linearna korelacija ne glede na funkcijo ledvic.
Roteas can be initiated or continued in patients who may require cardioversion. 
Pri bolnikih, ki bi lahko potrebovali kardioverzijo, je mogoče uvesti zdravilo Roteas ali nadaljevati z njegovo uporabo.
EU/1/16/1152/016 10 film-coated tablets EU/1/16/1152/017 14 film-coated tablets EU/1/16/1152/018 28 film-coated tablets EU/1/16/1152/019 30 film-coated tablets EU/1/16/1152/020 56 film-coated tablets EU/1/16/1152/021 60 film-coated tablets EU/1/16/1152/022 84 film-coated tablets EU/1/16/1152/023 90 film-coated tablets EU/1/16/1152/024 98 film-coated tablets EU/1/16/1152/025 100 film-coated tablets EU/1/16/1152/026 10 x 1 film-coated tablets EU/1/16/1152/027 50 x 1 film-coated tablets EU/1/16/1152/028 100 x1 film-coated tablets 
EU/1/16/1152/01610 filmsko obloženih tablet EU/1/16/1152/01714 filmsko obloženih tablet EU/1/16/1152/018 28 filmsko obloženih tablet EU/1/16/1152/019 30 filmsko obloženih tablet EU/1/16/1152/020 56 filmsko obloženih tablet EU/1/16/1152/021 60 filmsko obloženih tablet EU/1/16/1152/022 84 filmsko obloženih tablet EU/1/16/1152/023 90 filmsko obloženih tablet EU/1/16/1152/024 98 filmsko obloženih tablet EU/1/16/1152/025 100 filmsko obloženih tablet EU/1/16/1152/026 10 x 1 filmsko obložena tableta EU/1/16/1152/027 50 x 1 filmsko obložena tableta EU/1/16/1152/028 100 x 1 filmsko obložena tableta
Table 1: Summary of posology in NVAF and VTE (DVT and PE) Summary Guide for Dosing 
Preglednica 1: Povzetek odmerjanja pri NVAF in VTE (GVT in PE)
Uncommon (may affect up to 1 in 100 people): 
Občasni(pojavijo se lahko pri največ 1 od 100 bolnikov):
Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa assay which may help to inform clinical decisions in particular situations as, e.g. overdose and emergency surgery (see also section 5.2). 
Čeprav pri zdravljenju z edoksabanom ni potrebno rutinsko spremljanje,lahko njegov vpliv na antikoagulacijo ocenimoskalibriranim kvantitativnim testomanti-Xa, ki lahko v določenih primerih, npr. pri prevelikem odmerjanju in nujnem kirurškem posegu, pomaga pri klinični odločitvi (glejte tudi poglavje 5.2).
No dose modification is necessary when Roteas is administered with digoxin. 
Tega niso imeli za klinično pomembno.Nikakršno spreminjanje odmerka ni potrebno, kadar uporabljamo zdravilo Roteas z digoksinom.
Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Roteas. 
Pri uporabi zdravila Roteas so poročali o znanih sekundarnih zapletih po hudi krvavitvi, kot sta utesnitveni sindrom in odpoved ledvic zaradi hipoperfuzije.
Edoxaban 60 mg (30 mg Dose Reduced) (N = 4,118) 
Edoksaban 60 mg (zmanjšani odmerek 30 mg) (N = 4.118)
Early administration of activated charcoal may be considered in case of edoxaban overdose to reduce absorption. 
V primeru prevelikega odmerka edoksabana pride v poštev čimprejšnja uporaba aktivnega oglja za zmanjšanje absorpcije.
They come in blisters in cartons of 10 film-coated tablets or unit dose blisters in cartons of 10 x 1 filmcoated tablets. 
Na voljo so v pretisnih omotih v kartonskih škatlah s po10filmsko obloženimi tabletamiali v enoodmernih pretisnih omotihv kartonskih škatlah s po 10 x 1filmsko obloženo tableto.
Blood and lymphatic system disorders Anaemia 
Bolezni krvi in limfatičnega sistema anemija pogosti trombocitopenija občasni
Prosthetic heart valves and moderate to severe mitral stenosis Edoxaban has not been studied in patients with mechanical heart valves, in patients during the first 3 months after implantation of a bioprosthetic heart valve, with or without atrial fibrillation, or in patients with moderate to severe mitral stenosis. 
Pri bolnikih z mehaničnimi srčnimi zaklopkami, pri bolnikih prve 3 mesece po vsaditvi bioprotetične srčne zaklopke z atrijsko fibrilacijo ali brez nje in pri bolnikih z zmerno do težko mitralno stenozo edoksabana niso proučevali.
Table 12: Edoxaban Anti-FXa activity by creatinine clearance Edoxaban Dose 
Preglednica 12: Aktivnost edoksabana proti faktorju Xa glede na očistek kreatinina Odmerek edoksabana
Major Bleeding n (%) n 
Velika krvavitev n (%) n
Driving and using machines Roteas has no or negligible effects on your ability to drive or use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Roteasnima vpliva ali ima zanemarljivvpliv na sposobnost upravljanja vozil in strojev.
A specific anticoagulant reversal agent for edoxaban is not available (see section 4.9). 
Specifičnega sredstva, ki bi nevtraliziralo antikoagulantni učinek edoksabana, nimamo na voljo (glejte poglavje 4.9).
In patients with mild renal impairment (CrCL > 50 - 80 mL/min), the recommended dose is 60 mg Roteas once daily. 
Pri bolnikih z blago okvaro ledvic (CrCL > 50 - 80 ml/min) je priporočeni odmerek 60 mg zdravila Roteas enkrat na dan.
• Bleeding from a surgical wound following an operation 
• krvavitev iz kirurške ranepo operaciji,
In the Hokusai-VTE study the Net Clinical Outcome (Recurrent VTE, Major Bleed, or All-Cause Mortality; mITT population, overall study period) HR (95% CI) was 1.00 (0.85, 1.18) when edoxaban was compared to warfarin. 
V študiji Hokusai-VTE je bil neto klinični izid (recidivni VTE, velika krvavitev ali smrtnost ne glede na vzrok; populacija mITT, celotno obdobje študije) HR (95 % CI) 1,00 (0,85; 1,18), ko so edoksaban primerjali z varfarinom.
The duration of therapy was at least 3 months for 3,718 (91.6%) edoxaban subjects versus 3,727 (91.4%) of warfarin subjects; at least 6 months for 3,495 (86.1%) of edoxaban subjects versus 3,491 (85.6%) of warfarin subjects; and 12 months for 1,643 (40.5%) edoxaban subjects versus 1,659 (40.4%) of warfarin subjects. 
Trajanje terapije je bilo vsaj 3 mesece pri 3.718 (91,6 %) preiskovancih, zdravljenih z edoksabanom, proti 3.727 (91,4 %) preiskovancih z varfarinom; vsaj 6 mesecev pri 3.495 (86,1 %) preiskovancih z edoksabanom proti 3.491 (85,6 %) preiskovancih z varfarinom; in 12 mesecev pri 1.643 (40,5 %) preiskovancih z edoksabanom proti 1.659 (40,4 %) preiskovancih z varfarinom.
Periodic hepatic monitoring is recommended for patients on Roteas treatment beyond 1 year. 
Pri bolnikih, ki se zdravijo z zdravilom Roteas dalj od 1 leta, je priporočljivo spremljanje funkcije jeter v rednih presledkih.
HR (95% CI) p-value 
HR (95 % CI) vrednost p
For patients currently on a 30 mg dose (for one or more of the following clinical factors: moderate to severe renal impairment (CrCL 15 - 50 mL/min), low body weight, or use with certain P-gp inhibitors), administer a Roteas dose of 15 mg once daily together with an appropriate VKA dose. 
Bolnikom, ki trenutno prejemajo 30-miligramski odmerek (zaradi enega ali več naslednjih kliničnih dejavnikov: zmerna do huda okvara ledvic (CrCL 15 - 50 ml/min), majhna telesna masa ali uporaba z določenimi inhibitorji P-gp), dajte 15-miligramski odmerek zdravila Roteas enkrat na dan skupaj z ustreznim odmerkom VKA.
SSRIs/SNRIs: As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets (see section 4.4). 
SSRI/SNRI: tako kot pri drugih antikoagulantih je ob sočasni uporabi SSRI ali SNRI zaradi njihovega poročanega učinka na trombocite nevarnost krvavitve lahko zvečana (glejte poglavje 4.4).
EU/1/16/1152/003 10 film-coated tablets EU/1/16/1152/004 14 film-coated tablets EU/1/16/1152/005 28 film-coated tablets EU/1/16/1152/006 30 film-coated tablets EU/1/16/1152/007 56 film-coated tablets EU/1/16/1152/008 60 film-coated tablets EU/1/16/1152/009 84 film-coated tablets EU/1/16/1152/010 90 film-coated tablets EU/1/16/1152/011 98 film-coated tablets EU/1/16/1152/012 100 film-coated tablets EU/1/16/1152/013 10 x 1 film-coated tablets EU/1/16/1152/014 50 x 1 film-coated tablets EU/1/16/1152/015 100 x1 film-coated tablets 
EU/1/16/1152/00310 filmsko obloženih tablet EU/1/16/1152/00414 filmsko obloženih tablet EU/1/16/1152/005 28 filmsko obloženih tablet EU/1/16/1152/006 30 filmsko obloženih tablet EU/1/16/1152/007 56 filmsko obloženih tablet EU/1/16/1152/008 60 filmsko obloženih tablet EU/1/16/1152/009 84 filmsko obloženih tablet EU/1/16/1152/010 90 filmsko obloženih tablet EU/1/16/1152/011 98 filmsko obloženih tablet EU/1/16/1152/012 100 filmsko obloženih tablet EU/1/16/1152/013 10 x 1 filmsko obložena tableta EU/1/16/1152/014 50 x 1 filmsko obložena tableta EU/1/16/1152/015 100 x 1 filmsko obložena tableta
A total of 5 (0.5%, 95% CI 0.15% - 1.06%) events occurred in subjects in the edoxaban group (N = 1095) and 11 (1.0%, 95% CI 0.50% - 1.78%) events in the warfarin group (N = 1104); OR 0.46 (95% CI 0.12 - 1.43); ITT analysis set overall study period with mean duration of 66 days. 
Pri osebah v skupini z edoksabanom (N = 1095) je prišlo do skupno 5 dogodkov (0,5 %, 95-% IZ 0,15 %-1,06 %), pri osebah v skupini z varfarinom (N = 1104) pa do 11 dogodkov (1,0 %, 95-% IZ 0,50 %-1,78 %); razmerje obetov 0,46 (95-% IZ 0,12-1,43); analiza ITT je zajemala celotno obdobje študije s povprečnim trajanjem 66 dni.
Skin and subcutaneous tissue disorders Cutaneous soft tissue haemorrhage 
Bolezni kože in podkožja kožna krvavitev v mehkem tkivu pogosti
In patients with moderate or severe renal impairment (CrCL 15 - 50 mL/min), the recommended dose is 30 mg Roteas once daily (see section 5.2). 
Pri bolnikih z zmerno ali hudo okvaro ledvic (CrCL 15 - 50 ml/min) je priporočeni odmerek 30 mg zdravila Roteas enkrat na dan (glejte poglavje 5.2).
PVC/Aluminium blisters. 
Pretisni omoti iz PVC/aluminija.
INFORMATION IN BRAILLE Roteas 30 mg 
PODATKI V BRAILLOVI PISAVI Roteas 30 mg
Your doctor will tell you to reduce your dose of Roteas to a 30 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). 
Zdravnik vam bo naročil, da zmanjšajte odmerek zdravila Roteas na 30-miligramsko tableto enkrat na dan in jo jemljite skupaj z antagonistom vitamina K (n.pr.
There may be situations that warrant a change in anticoagulation therapy (Table 2). 
ko je upravičena sprememba antikoagulantne terapije (preglednica 2).
Primary Endpoint 
Primarno končno stanjea
Cartons of 10 film-coated tablets. 
Kartonske škatle s po 10 filmsko obloženimi tabletami.
Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE. 
nedavna operacija, poškodba, imobilizacija), dolgotrajna terapija pa naj temelji na trajnih dejavnikih tveganja ali idiopatski GVT ali PE.
The effect on prothrombin time (PT) and other coagulation biomarkers (e.g. anti-FXa, aPTT) was measured. 
Merili so vpliv na protrombinski čas (PT) in druge koagulacijske biomarkerje (n.pr.
30 mg and 60 mg film-coated tablets: 
30-miligramske in 60-miligramske filmsko obložene tablete:
Subcutaneous anticoagulant (i.e.: LMWH, fondaparinux): 
: heparin z majhno molekulsko maso (LMWH), fondaparinuks):
In the ENGAGE AF-TIMI 48 study there was a significant improvement in Net Clinical Outcome (First Stroke, SEE, Major Bleed, or All-Cause Mortality; mITT population, overall study period) in favour of edoxaban, HR (95% CI): 0.89 (0.83, 0.96); p = 0.0024, when edoxaban 60 mg treatment group was compared to warfarin. 
V študiji ENGAGE AF-TIMI 48 so ugotovili signifikantno izboljšanje neto kliničnega izida (prva možganska kap, SEE, velika krvavitev ali smrtnost ne glede na vzrok; populacija mITT, celotno obdobje študije) v korist edoksabana, HR (95 % CI): 0,89 (0,83, 0,96); p = 0,0024, ko so primerjali skupino, zdravljeno z edoksabanom 60 mg, s skupino, zdravljeno z varfarinom.
The co-administration of Roteas with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk (see section 4.5). 
Starejši Pri sočasnem dajanju zdravila Roteas in ASA pri starejših bolnikih moramo biti previdni zaradi možnega večjega tveganja krvavitve (glejte poglavje 4.5).
The results for all-cause mortality (adjudicated deaths) in Hokusai-VTE were 136 (3.3%) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 130 (3.2%) for warfarin. 
Rezultati za smrtnost ne glede na vzrok (po strokovni presoji) v študiji Hokusai-VTE so bili 136 (3,3 %) za preiskovance, ki so jemali edoksaban 60 mg (zmanjšani odmerek 30 mg), v primerjavi s 130 (3,2 %) za varfarin.
The plasma AUCs for subjects with mild (CrCL > 50 - 80 mL/min), moderate (CrCL 30 - 50 mL/min) and severe (CrCL < 30 mL/min but not undergoing dialysis) renal impairment were increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function. 
Plazemska AUC pri preiskovancih z blago (CrCL > 50 - 80 ml/min), zmerno (CrCL 30 - 50 ml/min) oziroma hudo (CrCL < 30 ml/min, vendar ti preiskovanci niso bili na dializi) okvaro ledvic se je zvečala za 32 %, 74 % oziroma 72 % v primerjavi z osebami z normalno funkcijo ledvic.
Compared to warfarin-treated subjects, the HR in the edoxaban 60 mg group was 0.87 (99% CI: 0.71, 1.07, p = 0.08 for superiority). 
V primerjavi s preiskovanci, zdravljenimi z varfarinom,je bilo HR v skupini z edoksabanom 60 mg 0,87 (99 % CI: 0,71, 1,07, p = 0,08 za superiornost).
The results for all-cause mortality (adjudicated deaths) in the ENGAGE AF-TIMI 48 study were 769 (3.99% per year) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 836 (4.35% per year) for warfarin [HR (95% CI): 0.91 (0.83, 1.01)]. 
Rezultati za smrtnost ne glede na vzrok (po strokovni presoji) v študiji ENGAGE AF-TIMI 48 so bili 769 (3,99 % na leto) za preiskovance, ki so jemali edoksaban 60 mg (zmanjšani odmerek 30 mg), v primerjavi z 836 (4,35 % na leto) za varfarin [HR (95 % CI): 0,91 (0,83; 1,01)].
Metabolism and biliary/intestinal excretion account for the remaining clearance. 
Presnova in izločanje preko žolča in črevesa predstavlja preostali očistek.
Roteas is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3). 
Okvara jeter Uporaba zdravilaRoteas je kontraindicirana pri bolnikih z boleznijo jeter, ki imajo hkrati motnje koagulacije in klinično pomembno tveganje za krvavitve (glejte poglavje4.3).
Interaction with other medicinal products affecting haemostasis Concomitant use of medicines affecting haemostasis may increase the risk of bleeding. 
Sočasna uporaba zdravil, ki vplivajo na hemostazo, lahko zveča nevarnost krvavitve.
This was not considered clinically relevant. 
Navedba smiselno ni potrebna.
60 mg once daily Dose recommendation for patients with one or more of the following clinical factors: Renal Impairment 
Priporočila za odmerjanje za bolnike z enim ali več naslednjih kliničnih dejavnikov:
For subjects presenting with PE (with or without DVT), 47 (2.8%) of edoxaban and 65 (3.9%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.73 (0.50, 
Od preiskovancev s klinično sliko PE (z GVT ali brez nje), je imelo 47 (2,8 %) preiskovancev z edoksabanom oziroma 65 (3,9 %) preiskovancev z varfarinom recidivni VTE [HR (95 % CI): 0,73
Signature of physician: 
Ime zdravnika:
There was a significant risk reduction in favour of edoxaban compared with warfarin for the primary safety endpoint of clinically relevant bleeding, a composite of major bleeding or clinically relevant non-major bleeding (CRNM), which occurred in 349 of 4,118 subjects (8.5%) in the edoxaban group and in 423 of 4,122 subjects (10.3%) in the warfarin group [HR (95% CI): 0.81 (0.71, 0.94); p = 0.004 for superiority]. 
Signifikantno bolj se je zmanjšalo tveganje pri edoksabanu kot pri varfarinu za primarno končno stanje varnosti klinično pomembne krvavitve, sestavljeno iz velike krvavitve ali klinično pomembne krvavitve, ki ni bila velika (CRNM), ki se je pojavila pri 349 od 4.118 preiskovancev (8,5 %) v skupini z edoksabanom in pri 423 od 4.122 preiskovancev (10,3 %) v skupini z varfarinom [HR (95 % CI): 0,81 (0,71, 0,94); p = 0,004 za superiornost].
Overdose with edoxaban may lead to haemorrhage. 
Preveliko odmerjanje edoksabana lahko povzroči krvavitev.
Parenteral option: Discontinue Roteas and administer a parenteral anticoagulant and VKA at the time of the next scheduled Roteas dose. 
Parenteralna opcija: ukinite zdravilo Roteas in bolniku dajte parenteralni antikoagulant in VKA ob času naslednjega načrtovanega odmerka zdravila Roteas.
There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving edoxaban. 
Pri osebah, ki prejemajo edoksaban, ni izkušenj z antifibrinolitičnimi zdravili (traneksamično kislino, aminokaprojsko kislino).
Talk to your doctor or pharmacist before taking Roteas, 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Roteasse posvetujte z zdravnikom ali farmacevtom,
Therefore Roteas should be used with caution in this population (see sections 4.4 and 5.2). 
Zato je treba zdravilo Roteas pri tej skupini bolnikov previdno uporabljati (glejte poglavji 4.4 in 5.2).
NAME OF THE MARKETING AUTHORISATION HOLDER Berlin-Chemie (logo) 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Berlin-Chemie AG
MARKETING AUTHORISATION NUMBER(S) 15 mg film-coated tablets: EU/1/16/1152/001-002 30 mg film-coated tablets: EU/1/16/1152/003-015 60 mg film-coated tablets: EU/1/16/1152/016-028 
15-miligramske filmsko obložene tablete: EU/1/16/1152/001-002 30-miligramske filmsko obložene tablete: EU/1/16/1152/003-015 60-miligramske filmsko obložene tablete: EU/1/16/1152/016-028
erythromycin, or ketoconazole, the recommended dose is one 30 mg tablet once daily. 
dronedaron, eritromicinali ketokonazol, je priporočeni odmerek ena 30-miligramska tableta enkrat na dan.
• Bleeding in the stomach 
• krvavitev v trebuhu,
P-gp Inhibitors 
Inhibitorji P-gp
Subjects in both edoxaban treatment groups had their dose halved if one or more of the following clinical factors were present: moderate renal impairment (CrCL 30 - 50 mL/min), low body weight (≤ 60 kg) or concomitant use of specific P-gp inhibitors (verapamil, quinidine, dronedarone). 
Preiskovancem v obeh skupinah zdravljenja z edoksabanom so odmerek prepolovili, če je bil prisoten eden ali več od naslednjih kliničnih dejavnikov: zmerna okvara ledvic (CrCL 30 - 50 ml/min), majhna telesna masa (≤ 60 kg) ali sočasna uporaba specifičnih inhibitorjev P-gp (verapamil, kinidin, dronedaron).
Roteas should be used with caution in patients with mild to moderate hepatic impairment (see section 4.4). 
Zdravilo Roteas je treba pri bolnikih z blago do zmerno okvaro jeter previdno uporabljati (glejte poglavje 4.4).
After taking renal function and body weight into account, age had no additional clinically significant effect on edoxaban pharmacokinetics in a population pharmacokinetic analysis of the pivotal Phase 3 study in NVAF (ENGAGE AF-TIMI 48). 
Po upoštevanju funkcije ledvic in telesne mase starost nima dodatnega klinično pomembnega vpliva na farmakokinetiko edoksabana v analizi populacijske farmakokinetike ključne študije faze 3 pri
1.23 × (140-age [years]) × weight [kg] (× 0.85 if female) serum creatinine [µmol/L] 
• Za kreatinin vµmol/l: 1,23 ×(140 - starost [v letih]) ×masa [kg] (× 0,85 pri ženskah) serumski kreatinin [µmol/l]
Secondary efficacy outcomes included the composite clinical outcome of recurrent VTE and all-cause mortality. 
Sekundarna kriterija učinkovitosti sta vključevala kombinacijo recidivnega VTE in smrtnosti ne glede na vzrok.
Stroke and SEE occurred in fewer subjects in the edoxaban 60 mg treatment group than in the warfarin group (1.57% and 1.80% per year, respectively), with a HR of 0.87 (99% CI: 0.71, 1.07, p = 0.0807 for superiority). 
Možganska kap in SEE sta se pojavila pri manj preiskovancih v skupini, zdravljeni z edoksabanom 60 mg, kot v skupini z varfarinom (1,57 % oziroma 1,80 % na leto), s HR 0,87 (99 % CI: 0,71, 1,07, p = 0,0807 za superiornost).
However, there is limited clinical experience with the use of this product in individuals receiving edoxaban. 
Vendar je pri osebah, ki prejemajo edoksaban, z uporabo tega zdravila malo kliničnih izkušenj.
The reduction in fatal bleeds was also significant for the edoxaban 60 mg treatment group compared with the warfarin group (0.21%, and 0.38%) [HR (95% CI): 0.55 (0.36, 0.84); p = 0.0059 for superiority], primarily because of the reduction in fatal ICH bleeds [HR (95% CI): 0.58 (0.35, 0.95); p = 0.0312]. 
Za skupino, zdravljeno z edoksabanom 60 mg, v primerjavi s skupino z varfarinom je bilo signifikantno tudi zmanjšanje smrtnih krvavitev (0,21 % oziroma 0,38 %) [HR (95 % CI): 0,55 (0,36, 0,84); p = 0,0059 za superiornost], predvsem zaradi zmanjšanja smrtnih ICH [HR (95 % CI): 0,58 (0,35, 0,95); p = 0,0312].
Changes observed in these clotting tests at the expected therapeutic dose are, however, small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of edoxaban. 
Pri pričakovanih terapevtskih odmerkih pa so spremembe vrednosti teh testov strjevanja krvi majhne, zelo spremenljivein niso koristne za spremljanje antikoagulantnega učinka edoksabana.
Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets. 
v primeru hude epistakse), kirurška hemostaza s postopki za nadzor krvavitev, nadomeščanje tekočine in hemodinamska podpora, dajanje krvnih pripravkov (koncentrirani eritrociti ali sveža zamrznjena plazma, odvisno od prisotnosti anemije ali koagulopatije) ali trombocitov.
The median study follow-up for both the edoxaban 60 mg and 30 mg treatment groups was 2.8 years. 
60 mg kot z edoksabanom 30 mg je bil 2,8 leta.
15 mg film-coated tablets: 
15-miligramske filmsko obložene tablete:
INFORMATION IN BRAILLE Roteas 60 mg 
PODATKI V BRAILLOVI PISAVI Roteas60 mg
Your doctor will need to do blood measurements and will instruct you when to start taking Roteas. 
Zdravnik vambo moral narediti preiskave krvi in vam bo naročil, kdaj začnite jemati zdravilo Roteas.
Table 5 shows ischaemic strokes/SEE by creatinine clearance category in NVAF patients in ENGAGE AF-TIMI 48. 
Preglednica 5 prikazuje ishemičnemožganske kapi/SEE po kategorijah očistka kreatinina pri bolnikih z NVAF v študiji ENGAGE AF-TIMI 48.
Clinically Relevant Bleeding (Major and CRNM)b, n (%) n 
(velika in CRNM),b n (%) n
INFORMATION IN BRAILLE Roteas 15 mg 
PODATKI V BRAILLOVI PISAVI Roteas15 mg
The pre-specified composite endpoints for the comparison of the edoxaban 60 mg treatment group to warfarin for stroke, SEE, and CV mortality HR (99% CI) was 0.87 (0.76, 0.99), MACE 0.89 (0.78, 1.00), and stroke, SEE, and all-cause mortality 0.90 (0.80, 1.01). 
Vnaprej specificirani sestavljeni kriteriji učinkovitosti za primerjavo skupine, zdravljene z edoksabanom 60 mg, z varfarinom za HR (99 % CI) možganske kapi, SEE in KV smrtnosti je bil 0,87 (0,76, 0,99), MACE 0,89 (0,78, 1,00) in možganska kap, SEE in smrtnost ne glede na vzrok 0,90
Event rate (%/year) 
n število dogodkov pogostnost dogodka (%/leto)
In the pivotal ENGAGE AF-TIMI 48 study (an event-driven, Phase 3, multi-centre, randomised, double-blind double-dummy parallel-group study), 21,105 subjects, with a mean CHADS2 score of 2.8, were randomised to either edoxaban 30 mg once daily treatment group, or edoxaban 60 mg once daily treatment group or warfarin. 
randomizirana, dvojno slepa dvojno prikrita študija 3. faze s paralelnimi skupinami) je bilo 21.105 preiskovancev s povprečnim rezultatom CHADS2 2,8, randomiziranih bodisi na skupino s terapijo z edoksabanom 30 mg enkrat na dan, bodisi na skupino s terapijo z edoksabanom 60 mg enkrat na dan bodisi z varfarinom.
Moderate or severe (CrCL 15 - 50 mL/min) 
okvara ledvic zmerna ali huda (CrCL 15 - 50 ml/min)
PC: 
P-gp: